Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials
ConclusionsThe findings of this analysis in patients with RA treated with baricitinib are consistent with a low risk to develop non-infectious ILD during baricitinib treatment, similar to that observed with other Janus kinase inhibitors.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Arthritis | Clinical Trials | Interstitial Lung Disease | Rheumatoid Arthritis | Rheumatology | Study